Research
Metabolic adaptation
Retatrutide achieves an 82.4% relative reduction in hepatic fat and normalizes liver fat in 86% of patients.
Retatrutide may be beneficial for patients with fatty liver disease.
StrongSupportsmedium confidence
Retatrutide demonstrates potent efficacy in resolving metabolic dysfunction-associated steatotic liver disease, achieving an 82.4% relative reduction in hepatic fat and normalization of liver fat in 86% of patients.
Why this rating
Based on Phase 2 clinical data from a controlled study.
Source
Triple Hormone Receptor Agonism: The Role of Retatrutide in Addressing Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Comprehensive Review
Ashwin A. Pillai et al. · Cardiology in Review · 2026
review
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →